Desvignes, C., Abi Rached, H., Templier, C., et al. (2017) BRAF Inhibitor Discontinuation and Rechallenge in Advanced Melanoma Patients with a Complete Initial Treatment Response. Melanoma Research, 27, 281-287.
ttps://doi.org/10.1097/CMR.0000000000000350

has been cited by the following article:

• TITLE: Asian Case of Metastatic Melanoma in Which a Complete Response Was Maintained after Discontinuation of Dabrafenib and Trametinib

  AUTHORS: Rikako Deno, Atsushi Tanemura, Madoka Takafuji, Yuma Hanaoka, Eiji Kiyohara, Noriko Arase, Mari Wataya-Kaneda, Manabu Fujimoto

  KEYWORDS: Metastatic Melanoma, Dabrafenib, Trametinib, Complete Response, Discontinuation

  JOURNAL NAME: Journal of Cosmetics, Dermatological Sciences and Applications, Vol.10 No.2, March 31, 2020

  ABSTRACT: A 54-year-old man diagnosed with metastatic melanoma of the right inguinal node with occult primary developed liver and bone metastases. The combination of dabrafenib plus trametinib was initiated, and a complete response (CR) was achieved 24 months after starting treatment. One month later, the target therapy was discontinued at the patient’s decision, and he has remained free from progression for 21 months since discontinuation. To the extent of our knowledge, real-world data in Asian melanoma concerning the discontinuation of dabrafenib plus trametinib after achieving CR have not been published; therefore, our case is a meaningful one for considering to cease target drugs and to rescue their financial toxicity.